Erratum: Church TJ, Haines ST. Treatment Approaches to Patients With Severe Insulin Resistance. Clinical Diabetes 2016;34:97–104 (DOI:10.2337/diaclin.34.2.97)

In the original print version of the article listed above, there was a typographical error in Table 2 on page 103. The weight effects of GLP-1 receptor agonists should have been depicted as two downward-pointing arrows instead of one upward-pointing arrow.

TABLE 2.

Pharmacological Treatment Options in the Setting of Severe Insulin Resistance

Medication Class	A1C Lowering*	Hypoglycemia Risk	Weight Effect	Ease of Use	Tolerability Issues	Relative Cost†
Treatment options that have been evaluated in patients with severe insulin resistance
GLP-1 receptor agonists	↓↓	←→	↓↓	Subcutaneous; once daily or once weekly	Nausea, vomiting	$$$

^*Additional A1C lowering in previously treated patients; ↓ = 0.5–1%, ↓↓ = 1–1.5%, ↓↓↓ = 1.5–2%.

^†Relative cost per 30-day supply; $ = <$100, $$ = $100–299, $$$ = $300–750, $$$$ = >$750 based on average wholesale price (54).

The corrected table row appears below. The online version of the article was revsied on 19 April 2016 to reflect this change.